Publication | Closed Access

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

Breast OncologyEsr1 MutationEndocrine-related CancerMedicinePharmacologyBreast CancerPharmacotherapyAromataseCancer TreatmentOncologyRadiation OncologyPalbociclib TherapyPhase 3